Skip to content
2000
Volume 25, Issue 5
  • ISSN: 1389-2037
  • E-ISSN: 1875-5550

Abstract

Background: Excessive insulin is the leading cause of metabolic syndromes besides hyperinsulinemia. Insulin-lowering therapeutic peptides have been poorly studied and warrant urgent attention. Objectives: The main purpose of this study, was to introduce a novel peptide COX that was initially isolated from the porcine small intestine and possessed the ability to inhibit insulin secretion under high-glucose conditions by modulating large conductance Ca2+-activated K+ channels (BK channels) activity. Methods and Results: Enzyme-linked immunosorbent assay results indicate that COX supressed insulin release induced by high glucose levels in pancreatic islets and animal models. Furthermore, electrophysiological data demonstrated that COX can increase BK channel currents and hyperpolarize cell membranes. Thus, cell excitability decreased, corresponding to a reduction in insulin secretion. Conclusion: Our study provides a novel approach to modulate high glucose-stimulated insulin secretion in patients with hyperinsulinemia.

Loading

Article metrics loading...

/content/journals/cpps/10.2174/0113892037249620231010063637
2024-06-01
2025-05-15
Loading full text...

Full text loading...

/content/journals/cpps/10.2174/0113892037249620231010063637
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test